



30 December 2024

**BEXIMCO PHARMACEUTICALS LIMITED**

**Annual General Meeting Statement**

Beximco Pharmaceuticals Limited ("Beximco Pharma", "BPL" or "the Company"; AIM Symbol: BXP, LEI No.: 213800IMBBB6TIOQGB56), the fast-growing manufacturer of generic pharmaceutical products and active pharmaceutical ingredients, today announces that all resolutions put before shareholders at the Company's Annual General Meeting ("AGM") held virtually on 29 December 2024 were duly passed.

The resolutions passed at the AGM included the approval of 40% cash dividend for the year ended on 30 June 2024. The cash dividend being 40% of the nominal value per ordinary share of Taka 10 (Taka 4.0 per ordinary share/per global depository receipt ("GDR") held in respect of GDR holders) will be paid to holders of ordinary shares/GDRs (who were on the register of shareholders/GDR holders' as on the date of record, i.e. 25 November 2024) on or before 28 January 2025. The cash dividend will be paid after deduction of taxes as per Bangladesh Tax law.

Additionally, the Special Resolution to change the name of the Company from "Beximco Pharmaceuticals Limited" to "Beximco Pharmaceuticals PLC." as per the provision of the Companies Act, 1994 (as amended in 2020) and to effect the change of the name in the relevant Clauses of the Memorandum and Articles of Association of the Company was passed. Further announcements will be made in due course when the name change will come into effect.

The Annual Report for 2023-24 is available from the Company's website, which includes the audited accounts and a review of operations for the year ended on 30 June 2024.

**For further information please visit [www.beximcopharma.com](http://www.beximcopharma.com) or enquire to:**

**Beximco Pharma**

S M Rabbur Reza, Chief Operating Officer  
Tel: +880 2 58611001, Ext. 20111

Mohammad Ali Nawaz, Chief Financial Officer  
Tel: +880 2 58611001, Ext. 20030

Mohammad Asad Ullah, FCS  
Executive Director & Company Secretary  
Tel: +880 2 41060531, Ext. 10140

**SPARK Advisory Partners Limited (Nominated Adviser)**

Mark Brady / Andrew Emmott  
Tel: +44 (0)20 3368 3551 / 3555

**SP Angel Corporate Finance LLP (Broker)**

Matthew Johnson  
Tel: +44 (0) 20 3470 0470

**FTI Consulting**

Simon Conway / Victoria Foster Mitchell / Sam Purewal  
Tel: +44 (0)20 3727 1000

**Notes to Editors**

**About Beximco Pharmaceuticals Limited**

Beximco Pharma is a leading manufacturer and exporter of medicines based in Bangladesh. Since its inception in 1976, the Company remains committed to health and wellbeing of people across all the continents by providing access to contemporary medicines. Company's broad portfolio of generics encompasses diverse delivery systems such as tablets, capsules, liquids, semi-solids, intravenous fluids, metered dose inhalers, dry powder inhalers, sterile ophthalmic drops, insulins, prefilled syringes, injectables, nebuliser solutions, oral soluble films etc. The Company also undertakes contract manufacturing for multinational and leading global generic pharmaceutical companies.

Beximco Pharma's state-of-the-art manufacturing facilities are certified by global regulatory authorities of USA, Europe, Australia, Canada, GCC and Latin America, among others and it has a geographic footprint in more than 50 countries. More than 6000 employees are driving the company towards achieving its aspiration to be among the most admired companies in the region.

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact [ms@seg.com](mailto:ms@seg.com) or visit [www.ms.com](http://www.ms.com).

RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our [Privacy Policy](#).

END

AGMKZMZZGLNGDZZ